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To evaluate the efficacy and safety of different bulking agents for treating urinary incontinence in women, a
systematic review including only randomized controlled trials was performed. The subjects were women with
urinary incontinence. The primary outcomes were clinical and urodynamic parameters. The results were
presented as a weighted mean difference for non-continuous variables and as relative risk for continuous
variables, both with 95% confidence intervals. Initially, 942 studies were identified. However, only fourteen
eligible trials fulfilled the prerequisites. Altogether, the review included 1814 patients in trials of eight different
types of bulking agents, and all studies were described and analyzed. The measured outcomes were evaluated
using a large variety of instruments. The most common complications of the bulking agents were urinary
retention and urinary tract infection. Additionally, there were certain major complications, such as one case of
death after use of autologous fat. However, the lack of adequate studies, the heterogeneous populations
studied, the wide variety of materials used and the lack of long-term follow-up limit guidance of practice. To
determine which substance is the most suitable, there is a need for more randomized clinical trials that compare
existing bulking agents based on standardized clinical outcomes.
KEYWORDS: Bulking Agents; Injections; Intraurethral Injections; Urinary Incontinence.
Matsuoka PK, Locali RF, Pacetta AM, Baracat EC, Haddad JM. The efficacy and safety of urethral injection therapy for urinary incontinence in
women: a systematic review. Clinics. 2016;71(2):94-100
Received for publication on October 23, 2015; First review completed on November 27, 2015; Accepted for publication on November 27, 2015
E-mail: pri.matsuoka@gmail.com
*Corresponding author
’ INTRODUCTION
Urinary incontinence is defined as the complaint of involun-
tary leakage of urine (1). This condition clinically presents as
urgency incontinence, stress urinary incontinence, or mixed
urinary incontinence, although stress urinary incontinence is the
most prevalent type in women.
There is a wide variety of both clinical and surgical treatment
approaches for incontinence. However, despite the large
number of surgical procedures available to treat urinary
incontinence, not all patients can benefit from the surgery
because the procedure-related risks (associated with the
patients’ clinical comorbidities) may outweigh the benefits of
this therapy. Furthermore, certain patients and especially those
with intrinsic sphincter deficiency and a fixed urethra, are
difficult to treat, showing poor results when subjected to
conventional surgery for urinary incontinence (2-5). For those
patients who present treatment failure, there are very few
alternatives to treat stress urinary incontinence. Bulking agents
are one option, offering less invasive augmentation of the
urethra than sling procedures and artificial sphincters (4-5).
For over a century, injection of urethral bulking agents has
been used in the treatment of urinary incontinence. Over the
past 50 years, this treatment modality has become more
popular, particularly due to the development of new
materials. In addition, this therapy deserves special attention
because it is a minimally invasive treatment with rapid
recovery and a low morbidity rate (6).
Regardless of the bulking agent used, the mechanism of
action of urethral injections involves reduction of the inner
diameter of the urethra. Thus, the final effect is coaptation of
the urethral lumen, which can lead to increased urethral
resistance and improvement in urinary incontinence.
Several agents have been used for urethral bulking.
However, in terms of efficacy and safety, no clear conclusions
can be drawn from trials to date to establish the best agent
for this treatment (7,8). Therefore, the aim of the present
study was to evaluate the efficacy and safety of the differentDOI: 10.6061/clinics/2016(02)08
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bulking agents used in urethral injection therapy for urinary
incontinence in women.
’ METHODS
Inclusion and exclusion criteria
Study selection. Randomized clinical trials were included.
Prospective, observational, cohort and case studies; letters;
reviews; and animal studies were excluded.
Patients. We selected studies analyzing adult female
patients with a diagnosis of urinary incontinence based on
clinical complaint and urodynamic investigation. There were
no restrictions on patients’ ethnicity or type of stress urinary
incontinence.
Intervention. We analyzed randomized clinical trials
that evaluated urethral injection techniques for the treatment
of urinary incontinence. These studies had to have compared
techniques for urethral bulking with each other or with a
different treatment modality, regardless of the type and
concentration of agents used and of the duration and
frequency of treatment. All studies assessing different
treatment techniques that did not include urethral bulking
or that switched interventions between groups during the
course of the study were excluded from our analysis. Studies
using stem cells or urethral injection after surgery for cancer
treatment or sex change were also excluded.
Clinical outcomes. The primary outcomes were divided
into clinical and urodynamic parameters. Clinical parameters
included symptom improvement (assessed by subjective
questions about clinical improvement), 24-hour pad test
results after the procedure, the impact on quality of life
(assessed by the King’s College Hospital Quality of Health
Questionnaire), voiding diary results and procedure-related
pain (assessed by 10-point Likert-type visual pain scales).
Regarding objective parameters, residual volume and other
data obtained from urodynamic investigation were evaluated.
We did not stratify these parameters according to the
assessment time points described in the primary study. In
studies investigating the outcome at several time points, we
considered only data referring to the last assessment period.
Literature search strategy. A systematic literature
search was conducted using MEDLINE, Embase, Cochrane
and LILACS, including articles published until April 4th,
2015. For this purpose, we used a search strategy with high
sensitivity and low specificity, based on keywords and
synonyms for urinary incontinence, bulking agents, injec-
tions, and periurethral injections, without limits regarding
study design, dates, or country of origin. This strategy was
adjusted according to the search engine used by each
database.
Standardization of literature review
Study selection. All articles retrieved from each database
were initially screened based on information found in the title
and abstract and were grouped as selected or non-selected
studies. This distribution aimed at initial selection of studies
that could potentially be included. Articles that did not have
sufficient information in the title or abstract to allow us to
define a category were read in full and were subsequently also
classified as selected or non-selected studies.
All selected studies were reviewed and read in full. After
assessment of methodological quality, the articles were either
included or excluded from our study according to the previously
determined inclusion criteria. Moreover, the references of all
selected studies were analyzed to increase the sensitivity of the
systematic review. For the same purpose, all related articles were
also reviewed.
Two researchers independently performed the process of
screening the studies. At the end of this stage, the researchers
compared the selected studies, and any discrepancies were
resolved by consensus.
Assessment of methodological quality. All selected
studies were assessed for methodological quality by two
researchers according to the technique developed by Jadad
et al. in 1996 (9). Methodological quality assessment was not
used as an inclusion or exclusion criterion, but rather as a
predictor of the strength of the evidence provided by an
individual study.
Statistical analysis. Non-continuous variables are expressed
as the weighted mean difference and continuous variables are
expressed as the odds ratio, both followed by their respective
95% confidence intervals (CIs). The level of significance was set
at 5% (rejection of the null hypothesis at the 0.05 level).
’ RESULTS
A total of 942 studies were identified by the search strategy.
This included articles retrieved from each database searched,
related articles, and references obtained from the selected
studies. Of these articles, 802 were retrieved from MEDLINE/
PubMed; 137, from Embase; and 3, from LILACS.
After the initial screening, 28 studies were selected to be
read in full. However, only fourteen eligible trials fulfilled
the prerequisites for the systematic review. The flow chart of
the study selection is shown in Figure 1.
The included studies showed significant methodological
heterogeneity, with a broad range of treatment proposals
(Table 1). The methodological characteristics of the selected
studies and their main biases are summarized in Table 2.
In this review, 1814 patients were included. Altogether, the
review included fourteen trials of seven different types of
intraurethral injection: glutaraldehyde cross-linked collagen
(Contigent), a porcine dermal implant (Permacolt), solid
silicone elastomer (Macroplastiquet), autologous fat, pyr-
olytic carbon (Duraspheret), calcium hydroxyapatite (Coap-
titet), hydrogel (Bulkamidt) and dextran copolymer
(Zuidext). The first trial compared solid silicone with the
porcine dermal implant and showed an improvement of at
least 1 Stamey grade at 12 months (po0.001) in favor
of silicone. Stamey grading is specifically a 4-level scale
of incontinence severity, ranging from 0 (continent/dry) to
3 (total incontinence, regardless of activity) (12). Nevertheless,
for the other outcome measurements, such as quality of life,
pad test results, and patient and physician assessment, there
was no difference between silicone and porcine dermal
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implant efficacy (12). Another trial compared autologous fat
with placebo and did not show a significant difference in
efficacy (14). Moreover, one patient died because of pulmon-
ary embolism due to the autologous fat injection (15).
A study by Corcos et al. (7) compared collagen injections
with three surgical techniques. When using intent-to-treat
analysis, the success rate among patients treated with surgery
was slightly higher than the rate in the collagen group, with
a non-significant difference of -3.71% (p=0.334) (7). Use of
pyrolytic carbon was shown to be as effective as collagen
injections after 1 year of follow-up, and the required substance
volume was significantly lower using pyrolytic carbon (4).
Furthermore, there was no difference in Stamey grade with the
use of calcium hydroxyapatite compared with collagen (17). In
2009, Lightner et al. (16) also compared dextran copolymer
with collagen injections and the results at 12 months showed
a smaller proportion of women with no response in terms
of urinary leakage upon provocation testing using dextran
copolymer (16).
Moreover, Kuhn et al. (11) tested collagen injections at two
different anatomical sites. Continence was found in 66.6% of
patients in the midurethral group and in 60% in the bladder
neck group. Both midurethral and bladder neck collagen
injections improved patient satisfaction nearly equally, with
a small advantage for midurethral injections (10).
A trial carried out by Meulen et al. (14) compared silicone
injections with pelvic floor muscle exercises in patients who
had failed previous conservative treatment. Despite the fact
that in terms of subjective parameters, there was a significantly
greater increase in the incontinence-related Quality of Life
Questionnaire score in the silicone group compared with the
control group (p=0.017), in terms of objective parameters, there
was no difference between the groups. At the 3rd month, the
results of the pad test showed improvement, although without
a significant difference between the two groups (14). A study
by Ghoniem et al. (13) showed that silicone injection was
significantly more effective than collagen injections for the
treatment of stress urinary incontinence, primarily due to
intrinsic sphincter deficiency, with a 2.1% cure rate difference.
A study by Andersen (19) evaluated the clinical success of
pyrolytic carbon compared with collagen in the treatment of
stress urinary incontinence caused by intrinsic sphincter
deficiency and the results showed that 40% of pyrolytic
carbon-treated patients and 14% of collagen-treated patients
were dry. Moreover, a trial by Anders et al. (18) compared
silicone with collagen in patients with intrinsic sphincter
deficiency, and there was no difference in subjective or objective
parameters between the groups.
A study comparing dextran copolymer injected via the
periurethral and transurethral routes considered patients as dry
only if they had 100% improvement and no leakage episodes
(10). The mean improvement was not significantly different
between the two groups at the 3rd, 6th, and 12th months of
follow-up (10), although postoperative urinary retention was
significantly higher in the periurethral injection group
(po0.05) (10).
Finally, the clinical trial comparing collagen with poly-
acrylamide hydrogel (Bulkamid) showed a 50% or greater
decrease in leakage and urinary incontinence episodes at
12 months in both groups, but not between groups (27). At
12 months of follow-up, the responder rate (subjective
improvement or cure) was 77.1% (145 of 188 women) in the
hydrogel group and 70.0% (70 of 100) in the collagen group
(p=0.201).
The main results of the studies and the adverse effects of
the bulking agents are summarized in Table 2. The measured
outcomes were evaluated using a large variety of instru-
ments and the outcomes in the studies of silicone compared
Studies identified as 
potentially relevant to the 
systematic review (N=942)
(N = 2044)
Studies selected for full-text 
analysis
(N 8)
(N=27)
Studies included in the 
systematic review
(N=14)
Studies excluded:
Case series: 1
Letter to the editor: 1
Non-randomized clinical trial: 2
Retrospective cohort study: 1
Commentary: 1
Study of another disease: 1
Same studies retrieved from
PubMed and Embase: 7
Studies excluded due to 
irrelevance to the theme 
after title/abstract analysis
Figure 1 - Search strategies used to identify studies.
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Table 1 - Summary of the selected studies and their methodological quality.
No. Authors Intervention
(n)
Control
(n)
Type of
UI
Primary
outcome(s)
Secondary
outcome(s)
Follow-
up
Adverse
effect(s)
Criteria for
ISD
1 Schulz et al.
(2004) (10)
Periurethral
injection with
dextran
copolymer (20)
Transurethral
injection with
dextran
copolymer (20)
SUI (n=36)
MUI (n=4)
Patients dry only if
they had 100%
improvement and
no leakage episodes
Subjective
mean
improvement
1, 3, 6
and 12
months
Urinary
retention
MUCP o20
cmH2O and a
VLPP o60
cmH2O
2 Kuhn et al.
(2008) (11)
Midurethral
injection with
collagen TI (15)
Bladder neck
injection with
collagen TI (15)
SUI (n=30) Patient satisfaction
(VAS)
Cough test,
urethral resting
pressure,
functional
urethral length
6
weeks
and 10
months
Residual urine
(US)
NM
3 Bano et al.
(2005) (12)
Silicone TI (24) Porcine dermal
implant (27) [TI
(13)+ PI (14)]
SUI (n=50) Pad test Stamey, KCQ 6
weeks
and6
months
Urinary
retention, urge
incontinence
NM
4 Ghoniem et al.
(2009) (13)
Silicone TI (122) Collagen TI
(125)
SUI with ISD
(n=247)
Stamey I-QOL, pad test 1, 3, 6
and 12
months
Genitourinary
adverse effects
NM
5 Meulen et al.
(2009) (14)
Silicone TI (24) Pelvic floor
muscle
exercises (21)
SUI with
urethral
hypermobility
(n=45)
Pad test Stamey Patient global
impression,
I-QOL
3 and
12
months
Genitourinary
adverse effects,
leakage implant
NA
6 Lee et al.
(2001) (15)
Autologous fat
PI (35)
Placebo PI (33) SUI (n=68) Pad test UIQ, MUCP, LPP 1, 2, 3,
6, 9,
12, 18
and 24
months
UTI, liposuction
site infection,
urinary
retention, fat
embolism
NM
7 Corcos et al.
(2005) (7)
Collagen TI (64) Urinary
incontinence
surgery* (54)
MUI or SUI
(n=133)
Pad test Symptoms of
incontinence,
general QOL,
disease-specific
QOL, and
depression
1, 3, 6
and 12
months
Urinary
retention,
transient
hematuria,
urinary
infection,
voiding difficulty
NA
8 Lightner et al.
(2001) (4)
Pyrolytic
carbon TI (178)
Collagen TI
(177)
SUI with ISD
(n=355)
Pad test Stamey Adverse effects 1, 3, 6
and 12
months
Urinary
retention,
urgency
History and
VLPP o90
cmH2O
9 Lightner et al.
(2009) (16)
Dextran
polymer (143)
Collagen (88) SUI (n=344) The proportion of
womenwho achieved
a X50% reduction in
urinary leakage on
provocation testing
performed at baseline
presentation com-
pared with that at
12 months after the
last treatment
Stamey, pad
test, voiding
diary, I-QOL
1, 2, 3,
6 and
12
months
Urinary
retention,
urgency, Urinary
infection, pain
VLPP o100
cmH2O
10 Mayer et al.
(2007) (17)
Calcium
hydroxyapatite
(158) [TI (145)+
PI (13)]
Collagen (138)
[TI (123)+ PI
(15)]
SUI with ISD
(n=296)
Stamey QOL, pad test 12
months
NM NM
11 Anders et al.
(1999) (18)
Silicone (34) Collagen (26) SUI with ISD
(n=60)
Patient satisfaction,
KCQ
Symptoms of
incontinence,
frequency,
urgency, pad
test
60
months
NM NM
12 Andersen
(2002) (19)
Pyrolytic
carbon (26)
Collagen (26) SUI with ISD
(n=52)
Stamey Pad test 2.6 and
2.8
years
NM VLPP o90
cmH2O
13 Maher et al.
(2005) (20)
Silicone TI (23) Pubovaginal
sling (22)
SUI with ISD
(n=45)
Success rates,
complications, costs
SUDI, IIQ, pad
test
6
weeks
and 6,
12, and
60
months
Frequency,
nocturia,
urgency, urge
incontinence,
stress
incontinence,
voiding difficulty
MUCP o20
cmH2O
14 Sokol et al.
(2014) (27)
Polyacrylamide
hydrogel (229)
Collagen (116) SUI or stress-
predominant
mixed UI
The proportion of
women at the
12-month follow-up
with a X50%
decrease from
baseline in leakage,
as measured by the
24-hour pad test,
and a X50%
decrease from
baseline in the
self-reported daily
number of
incontinence
episodes
The proportion
of women dry
(4 gm or less) or
improved
according to
the 24-hour
pad test, ICIQ-
UI, patient
diary,
responder rate,
I-QOL
1, 3, 6,
9 and
12
months
Urinary
retention, de
novo urge
incontinence,
dysuria, excreted
bulking material,
hematuria,
nocturia non-
acute urinary
pain,urinary
tract infection
VLPP o100
cmH2O
* Surgeries for urinary incontinence included Burch surgery, sling procedures, and bladder neck suspension. UI - urinary incontinence; MUI - mixed urinary
incontinence; SUI - stress urinary incontinence; TI - transurethral injection; VAS - visual analog scale; NM - not mentioned; PI - periurethral injection;
KCQ - King’s College Hospital Quality of Health Questionnaire; Stamey - Stamey scoring system; I-QOL - Urinary Incontinence Quality of Life Scale; NA - not
applicable; UIQ - Urinary Incontinence Questionnaire; MUCP - maximal urethral closure pressure; LPP - leak point pressure; SUDI - Short Urinary Distress
Inventory; IIQ - Incontinence Impact Questionnaire; ISD - intrinsic sphincteric deficiency; ICIQ-UI - International Consultation on Incontinence Modular
Questionnaire-Urinary Incontinence Form.
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Table 2 - Main results of the selected studies and their main adverse effects.
No. Authors Bulking agent Previous
treatment
Results – Primary outcome Results – Secondary
outcome
Main adverse
effects
Necessity of
reinjection
1 Schulz et al.
(2004) (10)
Dextran
copolymer
Conservative
treatments*
Dry: PI 1/17 and TI 3/17
p=NS
12 months
Subjective mean
improvement: PI 37% in
6/17 and TI 36% in 7/17
p=NS
12 months
Urinary retention:
PI 6/20 and TI 1/20
po0.05
Yes, but number ND
2 Kuhn et al.
(2008) (11)
Collagen NM Patient satisfaction (VAS):
bladder neck (BN): median
of 8 (95% CI 5-9);
midurethral (MU): 8
(95% CI 7-10)
po0.05
10 months
MUCP: BN: increase,
po0.05; MU: increase,
po0.05
postoperative
Urinary retention:
BN 1/15 and
MU 4/15
ND
3 Bano et al.
(2005) (12)
Silicone and
PDI
PDI: sling (3)
colposuspension
(4); silicone: sling
(2) and (1)
Pad test: dry: silicone 15/24
and PDI 9/24
6 months
Stamey improvement:
silicone 14/24 and PDI 10/
24 at 6 months
KCQ: silicone 14/24 and
PDI 7/24 at 6 months
Urinary retention:
silicone 2/25 and
PDI 1/25
ND
4 Ghoniem et al.
(2009) (13)
Silicone and
collagen
Conservative
treatments*
Stamey improvement:
silicone 75/122 and
collagen 60/125
po0.05
12 months
I-QOL: NS difference
after treatment
Pad test: NS difference
after treatment
UTI: silicone 29/
122 and collagen
31/125
Pyelonephritis:
silicone 1/125
ND
5 ter Meulen
et al. (2009) (14)
Silicone vs.
PFME
Conservative
treatments*
Pad test: NS difference after
treatment at 3 months
Stamey: silicone:
improvement at 3 months,
po0.05
I-QOL: silicone showed
better results at
3 months, po0.05
Urinary retention:
silicone 19/24
Leakage of
implant: 2/24
5 ml silicone
administered in
2 women after
the 3 months
6 Lee et al.
(2001) (15)
Autologous fat
vs. placebo
(saline
injection)
19 in each group
received
conservative
treatments*
Pad test: NS difference
after treatment for
3 months
MUCP and LPP: NS
difference after
treatment for 3 months
One death due to
pulmonary fat
embolism
Urinary retention:
fat 6/35 and saline
0/33
UTI: fat 6/35 and
saline 3/33
3 injections in the
control group; in the
fat group 1/27
women received 2
injections, and 26
received
3 injections
7 Corcos et al.
(2005) (7)
Collagen vs.
surgery
NM Pad test: NS difference after
12 months
SF-36 and I-QOL: NS
difference after 12
months
Urinary retention:
collagen 11/20 and
surgery 9/45
UTI: collagen 0/20
and surgery 4/45
3 injections (interval
of 1 month)
8 Lightner et al.
(2001) (4)
Pyrolytic
carbon vs.
collagen
Conservative
treatment or
anti-
incontinence
surgical
procedures that
failed
Stamey improvement:
pyrolytic carbon 49/61 and
collagen 47/68
12 months
-------- Increased
incidence of
urinary retention
in the pyrolytic
carbon group
(16.9% vs. 3.4%)
p=0.001
Maximum of
5 injections
9 Lightner et al.
(2009) (16)
Dextran
polymer vs.
collagen
Conservative
treatments*
Dextran polymer was not
equivalent to collagen
in 12 months
Stamey, pad test, voiding
diary, I-QOL Dextran
polymer was not
equivalent to collagen
in 12 months
Urinary retention:
28% in the
dextran polymer
group
Maximum of
3 injections
10 Mayer et al.
(2007) (17)
CaHA vs.
collagen
Conservative
treatments*
Stamey: same efficacy for
CaHA and collagen at
12 months
QOL significant at
12 months
Urinary retention:
CaHA 52/158 and
collagen 45/138
Maximum of
3 injections
11 Anders et al.
(1999) (18)
Silicone vs.
collagen
UI surgery KCQ: NS difference after
60 months
---------- ND ND
12 Andersen
(2002) (19)
Pyrolytic
carbon (PC) vs.
collagen
ND Stamey improvement: PC
20/26 in 2.6 years and
collagen 16/26 in 2.8 years
Pad test: dry PC 10/25
and collagen 3/21
ND ND
13 Maher et al.
(2005) (20)
Silicone vs.
sling
Conservative
treatments*
Symptomatic and patient
satisfaction success greater
in the sling group at
6 months (po0.001)
Pad test, SUDI and IIQ:
NS difference after
6 months
Voiding
dysfunction:
silicone 1/23 and
sling 4/22
Urge
incontinence:
silicone 7/14 and
sling 4/13
5/22 required a top-
up transurethral
injection
14 Sokol et al.
(2014) (27)
Polyacrylamide
hydrogel vs.
collagen
Conservative
treatments*
Hydrogel demonstrated
non-inferiority (po0.003)
but not superiority (p=NS) to
collagen gel for the primary
efficacy end point (ITT)
ICIQ-UI and I-QOL results
showed considerable
improvement in each
treatment group, but
not between the groups
Implantation site
pain: collagen 9/
116 and hydrogel
28/229
Up to 3 injections
CaHA - calcium hydroxyapatite; IIQ - Incontinence Impact Questionnaire; ISD - intrinsic sphincter deficiency; KCQ - King’s College Hospital Quality of
Health Questionnaire; MUCP - maximum urethral closure pressure; MUI - mixed urinary incontinence; NS - not significant; PDI - porcine dermal implant;
PFME - pelvic floor muscle exercises; SF-36 - 36-item Short-Form Health Survey; SUDI - Short Urinary Distress Inventory; SUI - stress urinary incontinence;
I-QOL - Urinary Incontinence Quality of Life Scale; VLPP - Valsalva leak point pressure; ND - not described; * including hormone replacement therapy,
pelvic floor exercises, biofeedback, and functional electrical stimulation; TI - transurethral injection; VAS - visual analog scale; NM - not mentioned;
PI - periurethral injection, UTI - urinary tract infection; p - p value; NS - not statistically significant; VAS - visual analog scale; LPP - leak point pressure;
ITT - intention to treat.
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with collagen were measured at different times (at 6 months
in one study, at 12 months in the second study, and at 5 years
in the third study). Therefore, we could not perform a meta-
analysis with common variables of the studies.
’ DISCUSSION
Urinary incontinence is a highly prevalent comorbidity
among women, with a significant negative impact on quality
of life; thus, effective treatment is imperative (2). It is known
that due to associated comorbidities, many women are at
high surgical risk. In this context, injecting bulking agents to
treat stress urinary incontinence seems to be an attractive
concept. Most procedures can be performed using regional
or local anesthesia and even on an outpatient basis and the
procedure is minimally invasive (7,20).
There is a large and considerably varied body of literature
on this treatment technique. Several bulking agents have
been reported, such as Teflon, autologous fat, silicone micro-
implants, pyrolytic carbon, dextran polymer, collagen,
polyacrylamide hydrogel and porcine dermal implants.
However, there is no consensus as to the best agent and
injection technique, so an accurate systematic review on the
subject is warranted to evaluate existing information and
identify the most suitable approach for patients.
Although systematic reviews are classified as secondary
studies, they provide the best level of evidence to identify
and support approaches used in health interventions. Here,
we elaborated upon a systematic review including only
randomized clinical trials and extensively analyzed the
studies’ methodological quality.
The analysis varied from study to study. A study by
Schulz showed that neither objective (pad test results) nor
subjective outcome mean improvement in 12 months was
significantly different between the two standard routes of
bulking agent injection. However, there was more urinary
retention following injection via the transurethral route.
Moreover, the site of collagen injection, whether midurethral
or in the bladder neck, resulted in no difference in patient
satisfaction, with both groups achieving a high grade of
satisfaction within 10 months.
There are more data on collagen in the literature and
studies on this substance showed significant improvement in
the Stamey score but did not show differences in parameters
such as quality of life and pad test results.
A systematic review by Ghoniem and Miller (22) included
studies only on Macroplastique from 1990-2010. The authors
specifically performed a meta-analysis of clinical trials and
prospective, observational and cohort studies reporting
treatment outcomes (22). In contrast, in the present review,
we included only randomized clinical trials with the highest
level of evidence, without limitation to year of publication.
Despite these inclusion criteria, we noticed methodological
quality heterogeneity among the included studies, as showed
by the Jadad score, ranging from 2-4.
Comparing our review with a Cochrane Library review
performed by Kirchin et al., we can highlight that in their
study, quasi-randomized and randomized trials until May
2011 were included, whereas in ours, only randomized
clinical trials until April 2015 were included (28). Moreover,
the Cochrane review did not include the LILACS or Embase
database. According to our inclusion criteria, we excluded
studies using stem cells because the results of stem cell
therapy for urinary incontinence are not well established in
the literature, so the comparison would not be precise.
Our comparison of study results was hindered because of the
absence of a standardized method to assess patients’ symptoms
and the lack of a standardized concept of a successful surgical
procedure. In addition, this review selected fourteen studies
with seven different types of bulking agents, thus preventing us
from drawing conclusions that can be extrapolated to clinical
practice. Although there are currently good-quality studies,
methodological heterogeneity in the measurement of clinical
outcomes in primary studies leads to impossibility in comparing
results, which in turn hinders performance of a systematic meta-
analysis on the topic (23).
Therefore, we suggest that more randomized clinical trials
studying new substances that have already shown promising
results in non-randomized prospective studies should be
performed (24,25). To reduce bias, the studies should have the
same patient inclusion criteria and should exclude patients
with mixed urinary incontinence. The outcome measure
should include patients’ subjective evaluation of symptoms
of urinary incontinence using already-existent questionnaires
to evaluate urinary incontinence and pad test results. It is
important to highlight that although the Stamey scoring
system has its limitations, many studies have used this score.
The literature lacks studies with long-term follow-up of
bulking agents. In the present review, only three studies had
a follow-up longer than two years. There was a tendency for
the improvement in urinary incontinence to decrease over
time in these studies. Beyond that, the short-term analysis
from the studies does not give much information about
repeated injections or about the cost-effectiveness aspects of
both first and repeated treatments.
Based on the studies included in this systematic review, we
can say that the majority of bulking agents are safe, mainly
because they did not show major adverse effects, except for
the study using autologous fat, which had one death.
However, not all adverse events were covered because we
did not include case series with long-term follow-up, as
reported for Deflux (26); this study demonstrated that the
material itself was associated with more frequent pseudoabs-
cess and de novo urge incontinence.
The lack of adequate studies, the heterogeneous popula-
tions studied, the wide variety of materials used and the lack
of long-term follow-up limit guidance of practice. To
determine which substance is the most suitable, there is a
need for more randomized clinical trials that compare existing
bulking agents based on standardized clinical outcomes.
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